# CU Programme of Idarucizumab for Japanese Patients

> **NCT02831660** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1 (actual)

## Conditions studied

- Hemorrhage

## Interventions

- **DRUG:** idarucizumab

## Key facts

- **NCT ID:** NCT02831660
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-22
- **Primary completion:** 2016-09-16
- **Final completion:** 2016-09-16
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831660, "CU Programme of Idarucizumab for Japanese Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02831660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*